A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Summary

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Timeline

Start

2022-11-22

Primary completion

2024-12-19

Completion

2024-12-19

Outcome

Met primary endpoint

release “The middle concentration of 25mg/ml achieved a statistically significant improvement of visual acuity at 42 days (p=0.045).” pharmamar.com ↗

Drugs

Indications